About Dr. Emek Blair

Award-Winning Chemist

About Dr. Blair

Dr. Emek Blair earned his Bachelor of Science Degree in Chemistry from Occidental College in Los Angeles, Calif. before going on to earn his Doctorate in Chemistry from the University of California, Irvine. Over the past 13 years, Dr. Blair has developed, refined and implemented a proprietary and innovative method for manufacturing custom liposome formulas. Since the development of this method, Dr. Blair has won several awards from the scientific community and has two patents pending.

In 2010, Dr. Blair began formulating and licensing liposomal products to companies.

In early 2015, Dr. Blair founded Valimenta to provide B2B private label manufacturing for custom liposomal products, vitamin supplements, herbal extracts and energy/nutrition drinks. Valimenta uses the proprietary method developed by Dr. Blair which does not require high pressures, high temperatures or toxic synthetic chemicals.

Credentials & Experience 

Bachelor of Science Degree in Chemistry

Occidental College in Los Angeles, California 

Doctorate in Chemistry

University of California, Irvine

Founder of CELLg8®

All natural, proprietary and patent-pending method for manufacturing custom liposome formulas  

Founder of Valimenta Labs

B2B private label manufacturing for custom liposomal products, vitamin supplements, herbal extracts and energy/nutrition drinks.

Accomplishments

Dr. Blair has formulated upwards of 100 unique liposomal formulas that have successfully been brought to market by some of the largest brands in the world. Several of Dr. Blair’s formulas have been internationally recognized and awarded by the science and supplement industries.

Dr. Blair continues to perform clinical trials with various high-impact medical doctors around the world; this research shows how natural products, when properly delivered, are critical to maximizing health.

Dr. Emek Blair standing in front of a black screen

Publications

 

  • Blair E.: “Next Generation of Liposomal Delivery for Cannabidiol From a Hemp Extract: A Safety Study” American Journal of Endocannabinoid Medicine, 2019 Nov; p 20-22.
  • Davis JL, Paris HL, Beals JW, Binns SE, Giordano GR, Scalzo RL, Schweder MM, Blair E, Bell C.: “Liposomal-encapsulated Ascorbic Acid: Influence on Vitamin C Bioavailability and Capacity to Protect Against Ischemia-Reperfusion Injury.” Nutr Metab Insights, 2016 Jun 20; 9:25-30.
  • Blair, E.; Stange, T.; “How Rouge Can Impact On-Line TOC Analyzers.” Ultrapure Water, Jan. 2008, p13-18 and Cover.
  • Stange, T.; Lu, Z.; Blair, E.; “Detection and Quantification of Carboxylic Acid Excursions in Ultrapure Water Using an On-line TOC Analyzer.” Semiconductor Pure water and Chemicals conference proceedings, 2007, 173-186.

Academic Publications:

  • Blair, E.; Sulc, F.; Farmer, P. J. “Biomimetic NOx Reductions by Heme Models and Proteins” N4 Macrocyclic Metal Complexes, J. H. Zagal, F. Bedioui, J. P. Dodelet eds. Springer, 2006, Chp. 4, pp. 149-190. (ISBN 0-387-29429-X)
  • Blair, E. “Electrochemical Degradation Pathways of 1,1,1-trichloroethane by Immobilized P450 CYP119 in Extreme Temperature and pH Environments.” Interface, 2005, 4; 54-55.
  • Kuznetsov, V.; Blair, E.; Farmer, P. J.; Poulos, T.; Peferitti, A.; Sevrioukova, I.; “The Putidaredoxin Reductase-Putidaredoxin Electron Transfer Complex: Theoretical and Experimental Study.” J.Biol.Chem. 2005, 280; 16135–16142.
  • Blair, E.; Greaves, J.; Farmer, P. J.; “High Temperature Electrocatalysis Using Thermophilic P450 CYP119: Dehalogenation of CCl4 to CH4.” J. Am.Chem. Soc. 2004, 126(28); 8632-8633.
  • Immoos, C.E.; Chou, J.; Bayachou, M.; Blair, E.; Farmer, P.J.; “Electrocatalytic Reductions of Nitrite, Nitric Oxide, and Nitrous Oxide by Thermophilic Cytochrome P450 CYP119 in Film- Modified Electrodes and an Analytical Comparison of Its Catalytic Activities with Myoglobin.” J. Am. Chem. Soc. 2004, 126(15); 4934-4942.
  • Blair, E.; Nikles, J. A.; Nikles, D. E.; Rogers, L. M.; Rogers, R. D.; Stabler, D.; Street, S. C.; “Molecular Structure of the Amine-Quinone Model Compound, 2,5-bis(dimethylamino)-1,4- benzoquinone.” Polymer Preprint, 2000, 41(1); 318.